CDKN2A and glioma: In addition to IDH1/2 mutation, MGMT promotor methylation, EGFR amplification, TERT promotor mutation, and CDKN2A/B homozygous deletion, we sought to elucidate the alterations of other potential molecular biomarkers that might provide clues for clinical decision-making in gliomas.